secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001193125-24-273953
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports 100% AML CR rate with INB-100 at ASH; no relapses after median 19.7 months
--------------------------------------------------------------------------------

- 100% of AML patients (n=10) remain in complete remission after median 19.7 months follow-up; no relapses or new deaths as of Sept 30, 2024.
- INB-100 shows durable in vivo expansion and persistence of allogeneic gamma-delta T cells at 365 days post single dose.
- No CRS, neurotoxicity (ICANS), or dose-limiting toxicities observed; low-grade GvHD steroid-responsive in 60% of patients.
- Expansion cohort enrollment ongoing at DL2 (RP2D); updated data expected first half 2025.
- Three patients in CR >3 years, one progression-free >4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524273953/0001193125-24-273953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524273953/d888773d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-273953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer